TY - JOUR
T1 - Homo and heteromultimetallic complexes containing a group 8 transition metal and µ-diphosphine bridging ligands involved in anticancer research
T2 - A review
AU - Roufosse, Basile
AU - Serbu, Christi
AU - Marschner, Christoph
AU - Prince, Sharon
AU - Blom, Burgert
N1 - Funding Information:
We thank Maastricht University and the Faculty of Science and Engineering for support.
Publisher Copyright:
© 2024 The Authors
PY - 2024/8/5
Y1 - 2024/8/5
N2 - Herein, we present a comprehensive review focusing on synthetic strategies, detailed structural analysis, and anticancer activity investigations of complexes following the general formula [LnM(µ-diphosphine)M'Lm] where M = group 8 metal; M’ = any transition metal; µ-diphosphine = bridging ligand; Ln and Lm = ligand spheres). Both homo- and heteromultimetallic complexes will be discussed in detail. We review in vitro, in vivo and in silico anticancer activity investigations, in an attempt to draw comparisons between the various complexes and derive structure-activity relationships (SAR). This review solely focuses on complexes falling under the general formula stated above that have been studied for their anticancer activities, other complexes falling into that scheme but which have not undergone anticancer testing are not included in this review. We compare the anticancer activities of these complexes to their mononuclear counterparts, and a positive control (cisplatin) when possible and present a summary of all existing data to date and attempt to draw some conclusions on the future development of these complexes.
AB - Herein, we present a comprehensive review focusing on synthetic strategies, detailed structural analysis, and anticancer activity investigations of complexes following the general formula [LnM(µ-diphosphine)M'Lm] where M = group 8 metal; M’ = any transition metal; µ-diphosphine = bridging ligand; Ln and Lm = ligand spheres). Both homo- and heteromultimetallic complexes will be discussed in detail. We review in vitro, in vivo and in silico anticancer activity investigations, in an attempt to draw comparisons between the various complexes and derive structure-activity relationships (SAR). This review solely focuses on complexes falling under the general formula stated above that have been studied for their anticancer activities, other complexes falling into that scheme but which have not undergone anticancer testing are not included in this review. We compare the anticancer activities of these complexes to their mononuclear counterparts, and a positive control (cisplatin) when possible and present a summary of all existing data to date and attempt to draw some conclusions on the future development of these complexes.
KW - Anticancer studies
KW - Bimetallic complexes
KW - Bridging ligands
KW - Diphosphine ligands
KW - Heteromultimetallic complexes
KW - Homomultimetallic complexes
U2 - 10.1016/j.ejmech.2024.116528
DO - 10.1016/j.ejmech.2024.116528
M3 - (Systematic) Review article
SN - 0223-5234
VL - 274
JO - European Journal of Medicinal Chemistry
JF - European Journal of Medicinal Chemistry
M1 - 116528
ER -